Résumé
Objective: To investigate the chemical constituents from whole herbs of Azolla imbricata. Methods: The chemical constituents were separated and purified by various chromatographic techniques of silica gel, ODS, Sephadex LH-20 gel, and semi-preparative HPLC. Their structures were identified by NMR and MS spectroscopic methods. Results: Twenty compounds were isolated from A. imbricata and identified as chlorogenic acid methyl ester (1), 4-O-caffeoylquinic acid (2), 3,4-O-dicaffeoylquinic acid methyl ester (3), 3,4,5-O-tricaffeoylquinic acid methyl ester (4), (-)-N-[3',4'-dihydroxy-(E)-cinnamoyl]-3-hydroxy-L-tyrosine (5), (-)-N-[3',4'-dihydroxy-(E)-cinnamoyl]-L-tyrosine (6), (-)-N-[3',4'-dihydroxy-(E)-cinnamoyl]-L-tyrosine methyl ester (7), (-)-N- [4'-hydroxy-(E)-cinnamoyl)]-L-tyrosine (8), brainicin (9), quercetin-3-O-β-D-glucoside (10), naringenin-7-O-β-D-glucoside (11), kaempferol-3-O-(6″-O-caffeoyl)-β-D-glucoside (12), caffeic acid (13), epirhododendrin (14), myzodendrone (15), trans-ferulic acid-β-D-glucoside (16), 5,7-dihydroxychromone-2-carboxylic acid (17), pinoresinol-4-O-β-D-glucoside (18), phytol (19) and trans-12-oxo-(10Z,15Z)-phytodienoic acid (20). Conclusion: Compounds 1-12, 14-18, and 20 are isolated from the genus Azolla for the first time and compound 19 is isolated from A. imbricata for the first time. Compounds 1-7, 10, 12, and 13 exhibit good antioxidant activity.
Résumé
<p><b>OBJECTIVE</b>The aim of the study was to determine the prevalence and the distribution pattern of lesion site of intracranial vascular stenosis and to identify risk factors for the stenosis in patients with essential hypertension.</p><p><b>METHODS</b>A total of 231 consecutive inpatients with essential hypertension were included in this study. Patients with the history of cerebrovascular diseases and relevant neurological symptoms were excluded. Intracranial vascular stenosis (>50% diameter reduction) was detected using CT angiography (CTA).</p><p><b>RESULTS</b>Of 231 patients, 69 (29.87%) had intracranial artery stenosis. The most common stenosis site is middle cerebral artery (43.69%), followed by carotid siphon (20.39%). The stenosis in internal carotid arterial system (78.64%) was more common than in vertebrobasilar arterial system (21.56%, P < 0.05). The patients with intracranial vascular stenosis were older, had longer history of hypertension, higher levels of systolic blood pressure, higher plasma cholesterol, higher LDL-C. Lp (a), higher urinary microalbumin excretion, thicker ventricular septum, and lower levels of HDL-C than the patients without stenosis. Logistic analysis showed that systolic blood pressure (OR 1.650, 95% CI 1.134 - 2.400, P = 0.023), course of hypertension (OR 1.238, 95% CI 1.072 - 1.429, P = 0.006), LDL-C (OR 2.103, 95% CI 1.157 - 3.823, P = 0.014) and type 2 diabetes (OR 2.325, 95% CI 1.161 - 4.341, P = 0.011) were the independent risk factors of asymptomatic intracranial arterial stenosis.</p><p><b>CONCLUSIONS</b>Nearly 30% inpatients with essential hypertension had asymptomatic intracranial artery stenosis. The most common site of stenosis was middle cerebral artery. Hypertension, dyslipidemia and diabetes were risk factors for the development of intracranial arterial stenosis.</p>